Project Grant K99NS142566
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of California, San Francisco a Project Grant totaling $119,367.00 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective August 11, 2025, with completion targeted for July 31, 2027. This award funds research investigating the RNA-related function and dysfunction of tau protein in frontotemporal dementia (FTD), a...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $446,991 to the University of California, Los Angeles on August 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The project, titled "A Novel Diagnostic Assay for Parkinsonian Tauopathies," will develop innovative aptamer-based diagnostic assays to detect specific tau peptides (MTBR-tau275 and...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a five-year Project Grant of $238,410 to the University of California, San Francisco (UCSF) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective August 1, 2025 through July 31, 2030. This mentored career development award supports Dr. Sarah Kaufman's research into the mechanisms underlying tau aggregation and neurotoxicity in...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $3.1 million to the University of California, Los Angeles under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The four-year project, initiated August 1, 2025 and concluding July 31, 2029, focuses on developing and validating human induced pluripotent stem cell (iPSC)-derived hippocampal assembloids as a research model to...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded a $2.35 million Project Grant to The Regents of the University of California, San Francisco, under the Aging Research program (CFDA 93.866) to conduct comprehensive research on aberrant proteomes in tauopathy. The award, which commenced June 1, 2025, and extends through February 28, 2030, funds an interdisciplinary research initiative combining mass spectrometry-based proteomics and functional genomics expertise to...
- Federal Project Grant Award Summary The University of California, San Francisco received a $119,367 Project Grant award from the National Institute of Neurological Disorders and Stroke under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective September 1, 2025, through August 31, 2027. The award supports investigator-initiated research examining the role of novel activity-associated postsynaptic proteins in synaptic function. The...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the Scripps Research Institute a project grant of $145,588 on July 15, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This research project, extending through January 31, 2029, will investigate polyglutamate binding protein 1 (PQBP1) as a central regulator of inflammation in neurodegenerative diseases. The research...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant totaling $626,034 to The Regents of the University of California, San Francisco under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) on August 6, 2025, with completion targeted for June 30, 2030. This research initiative will identify cortical and brainstem regions contributing to preserved partial hand function...
- Federal Project Grant Award Summary The University of California, San Francisco received a $1,275,512 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) effective June 1, 2025, through May 31, 2027. This award funds research investigating how progranulin (PGRN) species impact TDP-43 (TAR DNA-binding protein 43) proteolysis and accumulation in age-related neurodegenerative diseases, including Alzheimer's disease (AD), frontotemporal...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of California, San Diego a $3.08 million Project Grant (CFDA 93.853: Extramural Research Programs in the Neurosciences and Neurological Disorders) effective September 12, 2025, with a completion date of June 30, 2029. This research award funds the development and application of multimodal single-cell spatial transcriptomics technology to elucidate the mechanisms underlying...
Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Regents of the University of California, San Francisco a $136,620 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective February 1, 2026, through January 31, 2028. This award funds research investigating the impact of pathological tau protein on neural circuit function in mouse models of Progressive Supranuclear Palsy (PSP), a rare neurodegenerative motor disorder. The research employs custom-built behavioral phenotyping systems to characterize gait and eye movement abnormalities associated with tau pathology in motor control regions, including the substantia nigra and midbrain nuclei, with the objective of understanding the mechanistic link between tau aggregation and the clinical motor symptoms characteristic of PSP. The research deliverables include empirical findings on circuit-level dysfunction resulting from pathological tau expression and characterization of two newly developed transgenic mouse models that recapitulate key PSP clinical features. These research products are intended to advance fundamental understanding of PSP pathophysiology and provide preclinical models for future therapeutic development targeting tau-related neurodegeneration. The work will be conducted at UCSF's San Francisco, California facility and contributes to NINDS's mission to reduce the burden of neurological disease through investigator-initiated basic and translational research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $136.6k | 1/22/26 |